Balyasny Asset Management
AVTX icon

Balyasny Asset Management’s Avalo Therapeutics AVTX Stock Holding History

Balyasny Asset Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9M Buy
861,711
+130,125
+18% +$2.06M 0.02% 833
2026
Q1 		$10.9M Buy
731,586
+292,274
+67% +$4.57M 0.01% 996
2025
Q4 		$7.98M Sell
439,312
-378,124
-46% -$6.38M 0.01% 1146
2025
Q3 		$10.4M Buy
+817,436
New +$7.03M 0.01% 1037
2022
Q3 		– Sell
-6
Closed -$8K – 2837
2022
Q2 		$8K Buy
+6
New +$8.03K ﹤0.01% 2604

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Balyasny Asset Management's AVTX Position: Q2 2026 in Review

Balyasny Asset Management increased its Avalo Therapeutics (AVTX) stake by 18% in Q2 2026, buying an estimated $2.06M and bringing the position to 861,711 shares worth $15.9M. The position accounts for 0.02% of the portfolio, ranked #833.

Balyasny Asset Management first reported a position in AVTX in Q2 2022 and has held it in 5 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Balyasny Asset Management held 861,711 shares of Avalo Therapeutics worth $15.9M as of Q2 2026.
  • Balyasny Asset Management bought 130,125 Avalo Therapeutics shares in Q2 2026, an estimated $2.06M.
  • Avalo Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q2 2026, its #833 holding.
  • Balyasny Asset Management first reported a position in Avalo Therapeutics in Q2 2022 and has held it in 5 quarters since.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.